Dairy cow mammitis staphylococcus aureus-Escherichia coli bigeminy polyvalent vaccine and preparation method thereof

A technology for Escherichia coli and dairy cow mastitis, which is used in antibacterial drugs, pharmaceutical formulations, bacterial antigen components, etc.

Inactive Publication Date: 2011-10-05
新疆维吾尔自治区畜牧科学院兽医研究所
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] In order to solve the actual production problem of dairy cow mastitis immune prevention in dairy cow breeding in my country, according to the situation of dairy cow mastitis pathogens in my country, the present invention provides a double-linked multivalent vaccine for preventing dairy cow mastitis Staphylococcus aureus-Escherichia coli and its preparation method

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Dairy cow mammitis staphylococcus aureus-Escherichia coli bigeminy polyvalent vaccine and preparation method thereof
  • Dairy cow mammitis staphylococcus aureus-Escherichia coli bigeminy polyvalent vaccine and preparation method thereof
  • Dairy cow mammitis staphylococcus aureus-Escherichia coli bigeminy polyvalent vaccine and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0054] Embodiment 1: Cow mastitis Staphylococcus aureus-Escherichia coli dual multivalent vaccine, the vaccine comprises 4 parts of antigens by volume ratio, and the antigens include a, Staphylococcus aureus subspecies Staphylococcus aureus subsp.aureusCGMCC NO.4595, 4596, 4597, 4598 bacterial polysaccharide, protein mixture antigen combination; b, CGMCC NO.4595, 4596, 4597, 4598 toxin antigen combination; c, Escherichia coliCGMCC NO .4594 bacterial protein antigen; d, the toxin antigen of CGMCC NO.4594; and 6 parts of e, the composition of Montanide ISA70M VG immune oil adjuvant.

[0055]Among the 4 antigens, the combination of CGMCC NO.4595, 4596, 4597, and 4598 cell polysaccharide and protein mixture antigens contains 50%; CGMCC NO.4594 cell protein antigen contains 12.5%; CGMCC NO.4595, 4596, 4597 , 4598 toxin antigen combination contains 12.5%; CGMCC NO.4594 toxin antigen contains 25%.

[0056] The preparation method of the above-mentioned Staphylococcus aureus-Escherich...

Embodiment 2

[0093] Embodiment 2: Cow mastitis Staphylococcus aureus-Escherichia coli dual multivalent vaccine, the vaccine comprises 4 parts of antigens by volume ratio, and the antigens include a, Staphylococcus aureus subspecies Staphylococcus aureus subsp.aureusCGMCC NO.4595, 4596, 4597, 4598 the combination of any two of the bacterial polysaccharide and protein mixture antigens; b, the combination of any two of the CGMCC NO.4595, 4596, 4597, 4598 toxin antigens; c, The bacterial protein antigen of Escherichia coliCGMCC NO.4594; d, the toxin antigen of CGMCC NO.4594; and 6 parts of e, the composition of Montanide ISA70M VG immune oil adjuvant.

[0094] Among the 4 antigens, the combination of any two of CGMCC NO.4595, 4596, 4597, and 4598 bacterial polysaccharide and protein mixture antigens contains 50%; CGMCC NO.4594 bacterial protein antigen contains 12.5%; CGMCC NO.4595 , 4596, 4597, 4598 toxin antigen combination containing any two kinds of 12.5%; CGMCC NO.4594 toxin antigen conta...

Embodiment 3

[0096] Embodiment 3: Cow mastitis Staphylococcus aureus-Escherichia coli dual multivalent vaccine, the vaccine comprises 4 parts of antigens by volume ratio, and the antigens include a, Staphylococcus aureus subspecies Staphylococcus aureus subsp.aureusCGMCC NO.4595, 4596, 4597, 4598 the combination of any three of the bacterial polysaccharide and protein mixture antigens; b, the combination of any three of the CGMCC NO.4595, 4596, 4597, 4598 toxin antigens; c, The bacterial protein antigen of Escherichia coliCGMCC NO.4594; d, the toxin antigen of CGMCC NO.4594; and 6 parts of e, the composition of Montanide ISA70M VG immune oil adjuvant.

[0097] Among the 4 antigens, the combination of any three of CGMCC NO.4595, 4596, 4597, and 4598 cell polysaccharide and protein mixture antigens contains 50%; CGMCC NO.4594 cell protein antigen contains 12.5%; CGMCC NO.4595 , 4596, 4597, 4598 toxin antigen combination contains 12.5%; CGMCC NO.4594 toxin antigen contains 25%.

[0098] The ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a dairy cow mammitis staphylococcus aureus-Escherichia coli bigeminy polyvalent vaccine and a preparation method thereof. The vaccine comprises the following components in part by volume: 4 parts of antigens and 6 parts of Montanide ISA70MVG immune oil adjuvant, wherein the antigens comprise a, a combination of any two or more than two of antigens of thallus polysaccharide and protein mixtures of staphylococcus aureus subsp. aureus CGMCC No.4595, 4596, 4597 and 4598, b, a combination of any two or more than two of toxin antigens of CGMCC No.4595, 4596, 4597 and 4598, c, a thallus protein antigen of Escherichia coli CGMCC NO. 4594 and d, a toxin antigen of CGMCC No. 4594. The preparation method comprises the following steps of: preparing strains; preparing the thallus antigens; preparing the toxin antigens; and mixing the thallus antigens, the toxin antigens and the Montanide ISA70MVG immune oil adjuvant according to the volume ratio to obtain the vaccine. The invention has the advantages that: 1, the coverage area of vaccine strain antigens is wide, and the immunogenicity is high; 2, the effect is obvious; and 3, the safety of the vaccine is high.

Description

technical field [0001] The invention belongs to the field of biological vaccines and preparation thereof, in particular to a staphylococcus aureus-Escherichia coli dual multivalent vaccine of cow mastitis and a preparation method thereof. Background technique [0002] Mastitis in dairy cows is the most important infectious disease affecting milk yield and quality. According to research at home and abroad, the main pathogens of cow mastitis are divided into two categories: infectious pathogens and environmental pathogens. Infectious pathogens mainly include Staphylococcus aureus, Streptococcus agalactiae and Streptococcus dysgalactiae; environmental pathogens mainly include Escherichia coli, Streptococcus uberis and other Enterobacteriaceae bacteria. Foreign studies have shown that the isolation rate of Staphylococcus aureus in dairy cow mastitis cases is 15-50%, but the cure rate of mastitis caused by this bacteria during lactation is only 25%, so mastitis caused by this ty...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/116A61K39/108A61P31/04A61K39/09
Inventor 王治才王登峰
Owner 新疆维吾尔自治区畜牧科学院兽医研究所
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap